UCB (OTCMKTS:UCBJF) Sets New 52-Week High – What’s Next?

Shares of UCB SA (OTCMKTS:UCBJF) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $194.76 and last traded at $194.76, with a volume of 0 shares changing hands. The stock had previously closed at $194.76.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm’s 50 day moving average price is $180.54 and its two-hundred day moving average price is $156.04.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.